Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| OHRI ELEVATE Kidney Team Grants Competition | UNKNOWN |
| University of Ottawa Anesthesiology and Pain Medicine | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The PRO-Active rehabilitation prior to Kidney Transplantation to ImproVe patient-centered recovery Evaluation trial tests an approach where people are supported to exercise, improve diet, and receive emotional support at home before and after kidney transplant surgery to understand the ideal process and benefits.
Background: Many Canadians are waiting for a kidney transplant, using this wait time to improve health before surgery could mean better outcomes. Proactive rehabilitation (pro-hab) is an approach where people are supported to exercise, improve their diet, and have emotional support before surgery, and during their recovery at home.
Overarching Aim: The PROAKTIVE Pilot Trial will test an approach where people are supported to exercise, improve diet, and receive emotional support at home before and after kidney transplant surgery to understand the ideal process and benefits.
Methods:
Design, setting and participants: The PROAKTIVE Pilot trial is a single arm, prospective trial design where eligible participants are enrolled into the pro-hab program.
People >/= 18 years old who will undergo kidney transplant surgery will be included.
Intervention: The intervention will be a multimodal pro-hab program delivered for at least 4 weeks prior to transplant and for 18 weeks after discharge from transplant. The program will be supported virtually using an established, non-commercial platform available on computer, tablet or smartphone.
Outcomes and sample size: The outcomes are: enrollment, program adherence, patient-reported outcome follow-up. The sample size for this stage will be 45, which will provide 80% power to rule out <75% adherence (5% significance) based on our past experience achieving 90% adherence in related populations.
Expertise: Our team features multidisciplinary clinical and methodological experts, nationally representative knowledge users and patient representatives.
Expected outcomes: The PROAKTIVE Pilot Trial will develop, evaluate and implement a multimodal proactive rehabilitation (pro-hab) program that effectively improves patient-centered recovery and resource use for patient waiting for, and recovering after, kidney transplantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention (Pro-hab) | Experimental | The intervention is a multimodal pro-hab program delivered for at least 4 weeks prior to transplant and for 18 weeks after discharge from transplant surgery. The program will be supported virtually using an established, non-commercial platform available on computer, tablet or smartphone. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pro-hab program | Behavioral | Multimodal pro-hab program delivered for at least 4 weeks prior to transplant and for 18 weeks after discharge from transplant, including exercise, breathing, nutrition, and psychosocial support. |
| Measure | Description | Time Frame |
|---|---|---|
| Enrollment | >40% of eligible participants enroll (4/month) would allow us to complete a fully powered (n=312) patient trial in 24 months. | One month |
| Adequate pro-hab program adherence | >75% adherence is required to meaningfully benefit from multimodal health-promotion interventions. | A minimum of 4 weeks before surgery and 18 weeks after discharged from surgery |
| Adequate patient-reported outcome follow up | >90% complete outcome ascertainment ensures a low risk of bias trial in terms of non-missing data | One year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Inability to read and communicate in English
Cognitive impairment preventing ability to provide informed consent independently
No telephone/cell phone
Any of the following cardiovascular conditions:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel McIsaac, MD | Contact | 613-798-5555 | 14169 | dmcisaac@toh.ca |
| Emily Hladkowicz, PhD | Contact | 613-798-5555 | 18629 | emhladkowicz@toh.ca |
| Name | Affiliation | Role |
|---|---|---|
| Daniel McIsaac, MD | The Ottawa Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Ottawa Hospital | Ottawa | Ontario | K1H 8L6 | Canada |
Individual participant data, including data dictionaries, will be available. This includes individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). The Study Protocol, Statistical Analysis Plan and Informed Consent Form will also be made available. Data will be available beginning 3 months and ending 5 years following article publication of one year follow up data. Data will be shared with researchers who provide a methodologically sound proposal. Data can be used to achieve aims in a proposed proposal or for individual participant data meta-analysis. Proposals should be directed to the Principal Investigator. To gain access, data requestors will need to sign a data access agreement. Data will be shared via an appropriate 3rd party website that is consistent with ethical and health privacy compliant legislation at the time of study conclusion.
Data will be available beginning 3 months and ending 5 years following article publication of one year follow up data.
Data will be shared with researchers who provide a methodologically sound proposal. Data can be used to achieve aims in a proposed proposal or for individual participant data meta-analysis. Proposals should be directed to the Principal Investigator. To gain access, data requestors will need to sign a data access agreement. Data will be shared via an appropriate 3rd party website that is consistent with ethical and health privacy compliant legislation at the time of study conclusion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided